An unprecedented level of access to today’s best quantum hardware

Our partnerships provide Phasecraft with unique opportunities to scale development of our IP, inform the development of next-generation quantum hardware, and accelerate commercialisation of high-value breakthroughs.

Google Quantum AI

Google Quantum AI has developed some of the world’s leading quantum computers, based on superconducting qubit technology. Phasecraft has implemented its efficient algorithms on Google's quantum hardware. Our work together recently enabled us to develop the world’s most complex quantum ground-state simulation of the famous Fermi-Hubbard model in materials science.

IBM Quantum

IBM Quantum has a long history of groundbreaking work on the development of quantum hardware. The pulse-level control provided by IBM’s technology is the ideal fit for the quantum algorithms Phasecraft developed in the subcircuit model. By working as closely as possible with the hardware, we deliver orders-of-magnitude performance enhancements.


QuEra Computing is a world leader in commercialising quantum computing using neutral atoms. Based in Boston, and built on research undertaken at Harvard University and MIT, QuEra operates the world's largest publicly accessible quantum computer. QuEra’s technology is built on large-scale arrays of atoms, laser-cooled to microkelvin temperatures and held in vacuum by movable laser tweezers. QuEra’s first-generation machine, Aquila, a 256-qubit Quantum Processor is available on Amazon Braket.


Rigetti has developed the industry’s first multi-chip quantum processor for scalable quantum computing systems. In June 2022 they announced the launch of their first UK-based quantum computer. As Rigetti's partner, Phasecraft leads the quantum simulation component of this project.

Industry partners & collaborators


BT is one of the world’s leading communications services companies, serving the needs of customers in the UK and across 180 countries worldwide. BT’s main activities are the provision of fixed-line services, broadband, mobile and TV products and services as well as managed networked IT services. We are working with BT on the development of quantum algorithms and software for solving hard optimisation and constraint satisfaction problems, in particular those most relevant to the domain of telecoms networks.

Oxford PV

Oxford PV is the pioneer and technology leader in the field of perovskite solar cells. Established in 2010 as a spin-out from the University of Oxford, the company has grown to now claim both the largest global patent portfolio and the largest team exclusively focused on developing and commercialising perovskite-based solar technology. As of December 2020, its perovskite-on-silicon tandem solar cell technology holds the world record power conversion efficiency of 29.5%. We are working with Oxford PV on the development of new quantum algorithms and software to simulate currently intractable problems in materials modelling for photovoltaics.

Johnson Matthey

Johnson Matthey is a global specialty chemicals company and a leader in sustainable technologies, founded just over 200 years ago in London. Johnson Matthey’s principal activities are the manufacture of autocatalysts, heavy-duty diesel catalysts and pollution control systems, catalysts and components for fuel cells, catalysts and technologies for chemical processes, fine chemicals, chemical catalysts and active pharmaceutical ingredients, and the marketing, refining, and fabrication of precious metals. Our work with Johnson Matthey focused on the development of new tools for accurate materials modelling.


Roche is one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics, and a global supplier of transformative innovative solutions across major disease areas. Their strategy focuses on finding new medicines and diagnostics, and is grounded on scientific excellence. Our partnership with Roche has developed around the development of an understanding of the potential of near-term quantum technologies to revolutionise our ability to predict protein structures.